Smoking Cessation Support for Patients With Rheumatologic Diseases Via

Status Recruiting

Clinical Trial Summary

Smoking cessation support for patients with rheumatologist diseases is an underestimated issue. In the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. Among the willing group the highest quit rate was detected in the group that admitted to smoking cessation clinic. Therefore to increase the willingness to quit as well as to increase the Access to evidence based tobacco cessation support using new comminication technologies can be relevant. Investigators' aim in this study is to examine the effect of including WhatsApp in the routine smoking cessation practices on the quitting success of active smokers with rheumatic diseases who apply to the Rheumatology outpatient clinic.

Clinical Trial Description

In this randomized controlled study, the sample will be randomly divided to 2 arms. In one arm, usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. In the other arm, the intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp. Primary outcome measures will be the quit rate of both arms at 3rd, 6th and 12th month. Secondary outcomes will be access to evidence based smoking cessation support, admission rate of smoking cessation clinic and treatment use duration of cessation medications. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06219551
Study type	Interventional
Source	Recep Tayyip Erdogan University Training and Research Hospital
Contact	Dilek Karadogan
Phone	5063512295
Email	dilek.karadogan@erdogan.edu.tr
Status	Recruiting
Phase	N/A
Start date	November 10, 2023
Completion date	November 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06021652` - Feasibility, Adoption and Efficacy of A Virtual Reality Smoking Cessation Program for Patients Undergoing Lung Cancer Screening	N/A
Completed	`NCT02735382` - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study	N/A
Completed	`NCT02557919` - Families Reduce Exposure to Smoke at Home	N/A
Completed	`NCT01570595` - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV	Phase 1/Phase 2
Completed	`NCT00786149` - Improving Varenicline Adherence and Outcomes in Homeless Smokers	Phase 3
Completed	`NCT00387946` - Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)	Phase 3
Completed	`NCT00218452` - Smoking Cessation for Young Adults Who Binge Drink - 1	Phase 0
Completed	`NCT00124683` - Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1	Phase 2
Recruiting	`NCT04610931` - Study of the Effectiveness of a Virtual Reality Treatment in the Management of Smoking Cessation	N/A
Enrolling by invitation	`NCT06042361` - Enhancing Equity in Smoke-free Housing	N/A
Recruiting	`NCT04827420` - Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)	N/A
Recruiting	`NCT04994444` - Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts	Phase 2/Phase 3
Completed	`NCT05560243` - Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil	N/A
Completed	`NCT02721082` - Changing the Default for Tobacco Treatment	Phase 4
Completed	`NCT01885221` - A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation (UCare-ChewFree)	N/A
Completed	`NCT03445507` - Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care.	N/A
Completed	`NCT04540081` - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer	N/A
Completed	`NCT03714191` - Optimizing the Tobacco Cessation Clinical Decision Support Tool.
Completed	`NCT03553992` - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers	N/A
Completed	`NCT01699828` - Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Smoking Cessation Support for Patients With Rheumatologic Diseases Via WhatsApp

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms